Science

Jun 21, 2025, 11:47

Myeloma Paper of the Day, June 21st, suggested by Robert Orlowski

Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:

“Myeloma Paper of the Day: Daratumumab- and elotuzumab-based treatments for refractory POEMS syndrome -> 1 hematologic (8%), 7 VEGF (54%), 2 neurologic (15%) and 8 generalized clinical responses (62%); median time to next treatment was 11 months.”

Title: Daratumumab (anti-CD38)- and elotuzumab (anti-SLAMF7)-based treatments for refractory POEMS syndrome: a single-center case series

Authors: Tomoki Suichi, Sonoko Misawa, Kazumoto Shibuya, Marie Morooka, Moeko Ogushi, Nagisa Oshima-Hasegawa, Shokichi Tsukamoto, Yusuke Takeda, Naoya Mimura, Emiko Sakaida, Satoshi Kuwabara

You can read the Full Article in Hematology.

More posts featuring Robert Orlowski.

cancer Emiko Sakaida Kazumoto Shibuya Marie Morooka MM Moeko Ogushi Myeloma Myeloma Paper of the Day Nagisa Oshima-Hasegawa Naoya Mimura OncoDaily Oncology POEMS syndrome Robert Orlowski Satoshi Kuwabara Shokichi Tsukamoto Sonoko Misawa Tomoki Suichi Yusuke Takeda

Cardio-Oncology in Focus: How Chemotherapy Can Harm Heart Health

Oncologist Near Me – Razelle Kurzrock: Revolutionizing Cancer Treatment Through Precision Medicine

Smoking and Bladder Cancer: What You Need to Know to Protect Yourself

Cervical Cancer Screening: Who Needs a Pap Smear or HPV Test and When?

Clinical Trials in Cancer Care: What They Are, How to Join, and What to Expect